Fig. 7: PMD-026 is efficacious in syngeneic MPN mouse models.

a White blood cell count following drug treatment in the JAK2V617F mouse model. Mice were treated with control (n = 7), 50 mg/kg PMD-026 (n = 5), or 100 mg/kg PMD-026 (n = 5). Statistics were assessed by two-way ANOVA between treatment groups versus control. Data are presented as mean values +/− SD. b Altered hematopoietic and disease parameters following drug treatment in the MPLW515L mouse model. Mice were treated with control (n = 8), 90 mg/kg ruxolitinib (n = 8), 100 mg/kg PMD-026 (n = 8) or combination (n = 8). White blood cells, monocytes, hematocrit, and platelets were assessed by Hemavet. Statistics were assessed by two-way ANOVA between treatment groups as indicated. Data are presented as mean values +/− SD. Spleen and liver weights were normalized to mouse weights at the endpoint. Statistics were assessed by one-way ANOVA with Dunnett’s multiple comparisons test. c Kaplan-Meier survival analysis. Statistics were assessed by log-rank test between treatment groups as indicated. d Histology of femur bone marrow at endpoint. Images show representative H&E and reticulin staining from 3 mice per group. Scale bar = 100 μM. e Luminex multiplex assays detecting plasma cytokines of treated MPLW515L mice. Vehicle (n = 7), ruxolitinib (n = 5), PMD-026 (n = 7), combo (n = 7). Statistics assessed by two-tailed Student’s t test. Boxplot showing median, upper, and lower quartiles with whiskers representing highest and lowest values excluding outliers, and potential outliers.